Rescue Therapy of Refractory Diffuse Large B-Cell Lymphomas BCL2 with Venetoclax: Case Report
- 1 January 2020
- journal article
- research article
- Published by S. Karger AG in Chemotherapy
- Vol. 65 (5-6), 161-165
- https://doi.org/10.1159/000512541
Abstract
Eleven years ago, a 64-year-old Caucasian man had LNH Follicular 3a, IV A stage, FLIPI 2 as a prognostic index of follicular lymphoma. He received 8 cycles of RCHOP followed by rituximab maintenance, with complete remission. Due to a systemic recurrence, a new treatment schedule (RCOMP, 6 cycles) was introduced with partial remission persisting during a long-term maintenance treatment with rituximab. Three years ago, LNH Follicular 3a progressed into GC type diffuse large B-cell lymphomas (DLBCL); 6 cycles of rituximab and bendamustine were followed by R-ICE and R OXALI DHAP treatments without beneficial effect. Due to the worse general condition (ECOG 3–4), the patient was treated with pixantrone (6 cycles) until July 10, 2019, with a partial response. On Jan 13, 2020, an extreme compassioned treatment with venetoclax alone was started; this drug was well tolerated and provided a satisfactory clinical and laboratory improvement. In June 2020, however, he developed bone marrow toxicity and septic fever. Nasal and pharyngeal secretions were SARS-CoV-2 RNA negative. Blood cultures for mycotic agents and Gram-positive, Gram-negative, and anaerobic bacteria were negative, but few days later, the patients died of sepsis due to unidentified agents. The use of venetoclax as a single drug to treat DLBCL BCL2 patients deserves further investigation.Keywords
This publication has 31 references indexed in Scilit:
- Dermoscopic characterization of folliculotropic mycosis fungoides selectively localized on trunk and limbsInternational Journal of Dermatology, 2019
- Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trialBlood, 2019
- Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphomaLeukemia, 2019
- Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell LymphomasThe Oncologist, 2018
- Targeting BCL2 with venetoclax is a promising therapeutic strategy for “double-proteinexpression” lymphoma with MYC and BCL2 rearrangementsHaematologica, 2018
- Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell LymphomasClinical Cancer Research, 2018
- Bilateral Lacrimal Gland Involvement With Mantle Cell LymphomaThe American Journal of the Medical Sciences, 2015
- Transient reactivation of occult hepatitis B virus infection despite lamivudine prophylaxis in a patient treated for non-Hodgkin lymphomaInfection, 2012
- Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapyDigestive and Liver Disease, 2012
- Absence of occult hepatitis C virus infection in patients under immunosupressive therapy for oncohematological diseasesHepatology, 2011